These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25728682)

  • 1. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.
    Kanu N; Grönroos E; Martinez P; Burrell RA; Yi Goh X; Bartkova J; Maya-Mendoza A; Mistrík M; Rowan AJ; Patel H; Rabinowitz A; East P; Wilson G; Santos CR; McGranahan N; Gulati S; Gerlinger M; Birkbak NJ; Joshi T; Alexandrov LB; Stratton MR; Powles T; Matthews N; Bates PA; Stewart A; Szallasi Z; Larkin J; Bartek J; Swanton C
    Oncogene; 2015 Nov; 34(46):5699-708. PubMed ID: 25728682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.
    Carvalho S; Vítor AC; Sridhara SC; Martins FB; Raposo AC; Desterro JM; Ferreira J; de Almeida SF
    Elife; 2014 May; 3():e02482. PubMed ID: 24843002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SETD2 Methyltransferase Supports Productive HPV31 Replication through the LEDGF/CtIP/Rad51 Pathway.
    Mac M; DeVico BM; Raspanti SM; Moody CA
    J Virol; 2023 May; 97(5):e0020123. PubMed ID: 37154769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
    González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
    Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
    Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
    Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
    Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
    Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
    Li L; Miao W; Huang M; Williams P; Wang Y
    Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
    Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
    Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
    Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
    Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
    Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
    Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.
    Feng C; Ding G; Jiang H; Ding Q; Wen H
    Tumour Biol; 2015 May; 36(5):3457-64. PubMed ID: 25528216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
    Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
    Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A missense SNP in the tumor suppressor SETD2 reduces H3K36me3 and mitotic spindle integrity in Drosophila.
    Brockett JS; Manalo T; Zein-Sabatto H; Lee J; Fang J; Chu P; Feng H; Patil D; Davidson P; Ogan K; Master VA; Pattaras JG; Roberts DL; Bergquist SH; Reyna MA; Petros JA; Lerit DA; Arnold RS
    Genetics; 2024 Apr; 226(4):. PubMed ID: 38290049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
    Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
    Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.
    Pfister SX; Ahrabi S; Zalmas LP; Sarkar S; Aymard F; Bachrati CZ; Helleday T; Legube G; La Thangue NB; Porter AC; Humphrey TC
    Cell Rep; 2014 Jun; 7(6):2006-18. PubMed ID: 24931610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
    Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
    Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.